menu

Q&AD: Answering Your Questions About Early Alzheimer’s Detection

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Q&AD: Answering Your Questions About Early Alzheimer’s Detection

0.25 credits
15 minutes
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.25 credits
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Alzheimer’s disease (AD) is a progressive, irreversible, neurodegenerative disease that significantly impacts the lives of patients and their families, as well as society. AD is typically diagnosed later in the disease course, limiting time for psychoeducation, interventional strategies, and planning. Additionally, this delayed diagnosis leads to inefficient or unnecessary care, as well as higher costs, and causes harm to individuals and society. That is why detecting AD early is critically important.

    In the second part of this two-episode series, expert faculty will answer some of your questions pertaining to the early detection of AD.

    If you haven’t viewed the first part of this series, you can view it here.

  • Disclosure of Conflicts of Interest

    Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all financial relationship(s) with ineligible companies*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the launch of this activity.

    *The ACCME defines an ineligible company as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies – unless the provider of clinical service is owned, or controlled by, an ACCME-defined ineligible company.

    The following individuals have indicated that they have not had, in the past 24 months, a relevant financial relationship(s) with ineligible companies to disclose:

    • Planners (Forefront Collaborative): Valerie Siclari, PhD; Megan Ragan
    • Moderator: Jennifer Caudle, DO

    The following individuals have disclosed that they have had a financial relationship in the past 24 months that has been deemed relevant to this activity. All relevant financial relationships have been mitigated:

    Faculty Presenter: Alireza Atri, MD, PhD

    • Researcher: Athira, Alzheon, Biogen, Biohaven, Eisai, Eli Lilly, Vivoryon
    • Consultant/Advisor: AbbVie, Acadia, AZ Therapies, Biogen, Eisai, JOMDD, Lundbeck, Roche/Genentech, Novo Nordisk, and Qynapse

    Faculty Presenter: Sharon J. Sha, MD, MS

    • Researcher: Acadia, Biogen, Cortexyme, Eisai, Eli Lilly, Genentech, Novartis
    • Consultant: ExpertConnect, Guidepoint Global, Office Hours
  • Target Audience

    The target audience includes neurologists and others involved in the care of patients with dementia, including other physicians, nurse practitioners, and physician assistants.

  • Learning Objectives

    As a result of participation in this initiative, participants will increase their ability to:

    1. Utilize clinical approaches for early detection of suspected cognitive impairment due to AD
  • Accreditation and Credit Designation Statements

    Accreditation Statement
    Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Credit Designation Statement
    Forefront Collaborative designates this activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Disclaimer

    The views and opinions expressed in this activity are those of the faculty, and do not necessarily reflect the views or recommendations of Forefront Collaborative and Biogen.

    The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

    This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.

  • Provider(s)/Educational Partner(s)

    Provided by Forefront Collaborative.

  • Commercial Support

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Alzheimer’s disease (AD) is a progressive, irreversible, neurodegenerative disease that significantly impacts the lives of patients and their families, as well as society. AD is typically diagnosed later in the disease course, limiting time for psychoeducation, interventional strategies, and planning. Additionally, this delayed diagnosis leads to inefficient or unnecessary care, as well as higher costs, and causes harm to individuals and society. That is why detecting AD early is critically important.

    In the second part of this two-episode series, expert faculty will answer some of your questions pertaining to the early detection of AD.

    If you haven’t viewed the first part of this series, you can view it here.

  • Disclosure of Conflicts of Interest

    Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all financial relationship(s) with ineligible companies*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the launch of this activity.

    *The ACCME defines an ineligible company as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies – unless the provider of clinical service is owned, or controlled by, an ACCME-defined ineligible company.

    The following individuals have indicated that they have not had, in the past 24 months, a relevant financial relationship(s) with ineligible companies to disclose:

    • Planners (Forefront Collaborative): Valerie Siclari, PhD; Megan Ragan
    • Moderator: Jennifer Caudle, DO

    The following individuals have disclosed that they have had a financial relationship in the past 24 months that has been deemed relevant to this activity. All relevant financial relationships have been mitigated:

    Faculty Presenter: Alireza Atri, MD, PhD

    • Researcher: Athira, Alzheon, Biogen, Biohaven, Eisai, Eli Lilly, Vivoryon
    • Consultant/Advisor: AbbVie, Acadia, AZ Therapies, Biogen, Eisai, JOMDD, Lundbeck, Roche/Genentech, Novo Nordisk, and Qynapse

    Faculty Presenter: Sharon J. Sha, MD, MS

    • Researcher: Acadia, Biogen, Cortexyme, Eisai, Eli Lilly, Genentech, Novartis
    • Consultant: ExpertConnect, Guidepoint Global, Office Hours
  • Target Audience

    The target audience includes neurologists and others involved in the care of patients with dementia, including other physicians, nurse practitioners, and physician assistants.

  • Learning Objectives

    As a result of participation in this initiative, participants will increase their ability to:

    1. Utilize clinical approaches for early detection of suspected cognitive impairment due to AD
  • Accreditation and Credit Designation Statements

    Accreditation Statement
    Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Credit Designation Statement
    Forefront Collaborative designates this activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Disclaimer

    The views and opinions expressed in this activity are those of the faculty, and do not necessarily reflect the views or recommendations of Forefront Collaborative and Biogen.

    The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

    This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.

  • Provider(s)/Educational Partner(s)

    Provided by Forefront Collaborative.

  • Commercial Support

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule8 Aug 2022
Webpack App